While previous preclinical studies have shown that JAK-STAT inhibitors can reduce inflammation and provide neuroprotection in models of neurodegenerative disease [75, 76], our results are novel in demonstrating the divergent alteration of JAK-STAT signaling in AD and PD across both pathway enrichment and cell-cell communication analyses. This evidence concerns the gene SOAT1 and Alzheimer disease.